These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

66 related items for PubMed ID: 20215507

  • 1. A functional polymorphism in the NAD(P)H oxidase subunit CYBA is related to gene expression, enzyme activity, and outcome in non-Hodgkin lymphoma.
    Hoffmann M, Schirmer MA, Tzvetkov MV, Kreuz M, Ziepert M, Wojnowski L, Kube D, Pfreundschuh M, Trümper L, Loeffler M, Brockmöller J, German Study Group for High-Grade Non-Hodgkin Lymphoma.
    Cancer Res; 2010 Mar 15; 70(6):2328-38. PubMed ID: 20215507
    [Abstract] [Full Text] [Related]

  • 2. Genetic polymorphisms of NAD(P)H oxidase: variation in subunit expression and enzyme activity.
    Schirmer M, Hoffmann M, Kaya E, Tzvetkov M, Brockmöller J.
    Pharmacogenomics J; 2008 Aug 15; 8(4):297-304. PubMed ID: 17684477
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity.
    Wojnowski L, Kulle B, Schirmer M, Schlüter G, Schmidt A, Rosenberger A, Vonhof S, Bickeböller H, Toliat MR, Suk EK, Tzvetkov M, Kruger A, Seifert S, Kloess M, Hahn H, Loeffler M, Nürnberg P, Pfreundschuh M, Trümper L, Brockmöller J, Hasenfuss G.
    Circulation; 2005 Dec 13; 112(24):3754-62. PubMed ID: 16330681
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Efficacy of two different ProMACE-CytaBOM derived regimens in advanced aggressive non-Hodgkin's lymphoma. Final report of a multicenter trial conducted by GISL.
    Federico M, Clò V, Brugiatelli M, Carotenuto M, Gobbi PG, Vallisa D, Lombardo M, Avanzini P, Di Renzo N, Dini D, Baldini L, Silingardi V.
    Haematologica; 1998 Sep 13; 83(9):800-11. PubMed ID: 9825577
    [Abstract] [Full Text] [Related]

  • 10. Combined chemotherapy with carmustine, doxorubicin, etoposide, vincristine, and cyclophosphamide plus mitoxantrone, cytarabine and methotrexate with citrovorum factor for the treatment of aggressive non-Hodgkin lymphoma: a long-term follow-up study.
    Rigacci L, Carrai V, Nassi L, Alterini R, Longo G, Bernardi F, Bosi A.
    Cancer; 2005 Mar 01; 103(5):970-7. PubMed ID: 15666323
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Primary mediastinal large B-cell lymphoma (PMLBCL): long-term results from a retrospective multicentre Italian experience in 138 patients treated with CHOP or MACOP-B/VACOP-B.
    Todeschini G, Secchi S, Morra E, Vitolo U, Orlandi E, Pasini F, Gallo E, Ambrosetti A, Tecchio C, Tarella C, Gabbas A, Gallamini A, Gargantini L, Pizzuti M, Fioritoni G, Gottin L, Rossi G, Lazzarino M, Menestrina F, Paulli M, Palestro M, Cabras MG, Di Vito F, Pizzolo G.
    Br J Cancer; 2004 Jan 26; 90(2):372-6. PubMed ID: 14735179
    [Abstract] [Full Text] [Related]

  • 13. Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma.
    Lyman GH, Delgado DJ.
    Cancer; 2003 Dec 01; 98(11):2402-9. PubMed ID: 14635075
    [Abstract] [Full Text] [Related]

  • 14. DNA repair gene XRCC1 polymorphisms and haplotypes in diffuse large B-cell lymphoma in a Korean population.
    Kim IS, Kim DC, Kim HG, Eom HS, Kong SY, Shin HJ, Hwang SH, Lee EY, Kim S, Lee GW.
    Cancer Genet Cytogenet; 2010 Jan 01; 196(1):31-7. PubMed ID: 19963133
    [Abstract] [Full Text] [Related]

  • 15. Four versus six courses of a dose-escalated cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus etoposide (megaCHOEP) and autologous stem cell transplantation: early dose intensity is crucial in treating younger patients with poor prognosis aggressive lymphoma.
    Schmitz N, Kloess M, Reiser M, Berdel WE, Metzner B, Dorken B, Kneba M, Trumper L, Loeffler M, Pfreundschuh M, Glass B, German High-Grade Non Hodgkin's Lymphoma Study Group (DSHNHL).
    Cancer; 2006 Jan 01; 106(1):136-45. PubMed ID: 16331635
    [Abstract] [Full Text] [Related]

  • 16. [High-dose therapy and peripheral blood stem cell transplantation for patients with aggressive non-Hodgkin's lymphoma remaining in initial remission: results of a feasibility study].
    Kitajima H, Nasu K, Tsudo M, Fujimoto M, Hayashi K, Ohno H, Konaka Y, Katsurada T, Arima N, Doi S, Moriguchi T, Fukuhara S.
    Rinsho Ketsueki; 2001 Mar 01; 42(3):191-8. PubMed ID: 11345781
    [Abstract] [Full Text] [Related]

  • 17. A phase II multicenter trial of high-dose sequential chemotherapy and peripheral blood stem cell transplantation as initial therapy for patients with high-risk non-Hodgkin's lymphoma.
    Schenkein DP, Roitman D, Miller KB, Morelli J, Stadtmauer E, Pecora AL, Cassileth P, Fernandez H, Cooper BW, Kutteh L, Lazarus HM.
    Biol Blood Marrow Transplant; 1997 Oct 01; 3(4):210-6. PubMed ID: 9360783
    [Abstract] [Full Text] [Related]

  • 18. [Preliminary outcome for patients with relapsed or resistant advanced non-Hodgkin's lymphoma treated by EPOCH regimen].
    Huang HQ, Jiang WQ, Wang W, Zhou ZM, Xia ZJ, Lin XB, Li YH, Xu RH, Zhang L, Xu GC, Sun XF, Liu DG, He YJ, Guan ZZ.
    Ai Zheng; 2003 Apr 01; 22(4):389-92. PubMed ID: 12703995
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.